Acorda Therapeutics Inc. (ACOR)
NASDAQ: ACOR
· Real-Time Price · USD
0.66
-0.21 (-24.14%)
At close: Apr 03, 2024, 3:59 PM
Acorda Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 115.66M | 117.63M | 111.12M | 116.92M | 118.29M | 118.57M | 124.06M | 122.01M | 122.74M | 129.07M | 130.26M | 151.9M | 153.73M |
Cost of Revenue | 23.45M | 22.98M | 14.25M | 21.86M | 27.6M | 30.33M | 29.97M | 32.27M | 34.79M | 40.79M | 47.43M | 46.3M | 41.63M |
Gross Profit | 92.22M | 94.66M | 96.87M | 95.05M | 90.69M | 88.24M | 94.09M | 89.74M | 87.95M | 88.28M | 82.83M | 105.6M | 112.1M |
Operating Income | -24.3M | -17.24M | -14.41M | -21.45M | -34.85M | -38.99M | -54.86M | -68.3M | -66.96M | -79.04M | -145.87M | -106.83M | -100.69M |
Interest Income | 644K | 530K | 2.18M | 2.04M | 2M | 1.91M | 39K | 23K | 4K | 6K | 14K | 330K | 507K |
Pretax Income | -304.44M | -296.02M | -18.57M | -21.07M | -29.84M | -35.24M | -75.72M | -93.46M | -96.73M | -109.07M | -176.33M | -137.34M | -130.8M |
Net Income | -263.43M | -252.85M | -15.95M | -20.92M | -58.22M | -65.92M | -105.63M | -118.84M | -95.02M | -103.95M | -166.43M | -132.02M | -126.57M |
Selling & General & Admin | 95.55M | 89.7M | 93.75M | 93.59M | 101.83M | 106.26M | 108.44M | 115.07M | 117.37M | 124.4M | 128.84M | 139.15M | 145.44M |
Research & Development | 4.72M | 5.15M | 5.35M | 5.52M | 5.5M | 5.8M | 5.97M | 6.52M | 7.37M | 10.42M | 13.38M | 17.18M | 20.06M |
Other Expenses | 257K | 7.94M | 3.23M | 10.52M | 18.21M | 10.52M | 8.04M | -6.82M | -22.21M | -30.04M | -30.46M | -30.52M | -30.11M |
Operating Expenses | 116.3M | 117.92M | 117.3M | 117.32M | 125.54M | 130.27M | 145.17M | 152.35M | 155.5M | 165.58M | 172.98M | 187.09M | 196.25M |
Interest Expense | 32.8M | 32.31M | 28.94M | 28.58M | 28.34M | 28.33M | 29.84M | 29.54M | 29.77M | 30.04M | 30.46M | 31.05M | 30.83M |
Selling & Marketing Expenses | 381K | 381K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 139.75M | 140.9M | 131.55M | 139.19M | 153.14M | 160.6M | 175.14M | 184.62M | 190.29M | 206.37M | 220.41M | 233.38M | 237.89M |
Income Tax Expense | -41.02M | -43.17M | -2.63M | -155K | 28.37M | 30.67M | 29.91M | 25.38M | -1.71M | -5.12M | -9.9M | -5.33M | -4.23M |
Shares Outstanding (Basic) | 1.24M | 964.38K | 1.24M | 1.24M | 1.22M | 1.22M | 1.21M | 839.15K | 662.55K | 591.63K | 556.55K | 499.21K | 473.5K |
Shares Outstanding (Diluted) | 1.24M | 964.38K | 1.24M | 1.24M | 1.22M | 1.1M | 1.21M | 864K | 662.55K | 592.95K | 556.55K | 499.6K | 473.5K |
EPS (Basic) | -262.58 | -254.35 | -12.81 | -17.06 | -65.14 | -88.32 | -138.74 | -175.97 | -166.1 | -199.74 | -361.52 | -294.97 | -292.98 |
EPS (Diluted) | -262.58 | -254.35 | -19.78 | -24.03 | -70.51 | -93.69 | -137.21 | -174.44 | -166.21 | -199.85 | -361.56 | -295.02 | -293.02 |
EBITDA | 346K | 8.54M | 11.14M | 4.32M | -11.37M | -18.13M | -20.34M | -25.37M | -33.48M | -44.8M | -3.65M | -25.38M | -36.86M |
EBIT | -264.86M | -256.5M | 9.59M | 4.62M | -1.5M | -7.82M | -40.79M | -58.82M | -61.87M | -73.04M | -84.63M | -16.57M | -16.26M |
Depreciation & Amortization | 24.19M | 31.4M | 31.17M | 26.59M | 23.48M | 23.91M | 23.91M | 28.49M | 31.61M | 30.76M | 30.76M | 30.76M | 30.76M |